FluoGuide A/S met the primary endpoint in the initial part of its Phase 2 clinical trial for FG001. The study successfully identified 0.30 mg/kg as the optimal dose for surgical guidance in oral, head, and neck cancer patients.
The trial enrolled 15 patients who completed surgery with the drug being well-tolerated. All near-infrared imaging systems detected FG001 in every patient during the study.
FG001 targets cancer cells to light them up during surgery. This technology assists surgeons in removing tumors with increased precision.